Tagrisso 80mg Tablets| Osimeritinib Uses & Side effects

1
OSIMERITINIB 80MG TAGRISSO 80MG
MILLIONHEALTHPHARMA
2
DESCRIPTION

• A Tagrisso 80mg tablet is containing an active
  substance known as Osimeritinib, which is
  formerly known as Mereletinib.
• Tagrisso 80mg is considered as third generation
  medicine, which is available in tablet form.

3
(No Transcript)
4
DESCRIPTION

• Tagrisso 80mg is an inevitable, selectively
  deviated epidermal growth factor receptor
  prohibitor, containing anti-cancer activity.
• The pharmacological category of Tagrisso 80mg
  tablet is tyrosine kinase prohibitor.

5
INDICATION
6

• A Tagrisso 80mg tablet is widely indicated as
  first line therapy for advanced non-small cell
  lung cancer with EGFR mutation positive patients.
• Tagrisso 80mg tablet is also used for the
  treatment of patients affected with advanced EGFR
  T792M mutation positive NSCLC, disease has
  advanced on or after the tyrosine kinase
  inhibitor treatment.

7
MECHANISM OF ACTION
8
PROPERTIES

•   Ingredients Bevacizumab
•    Strength      100mg/4ml 
•   Package      400mg of Bevacizumab containing
  vial

9
ADME PROPERTIES

• Absorption
• High plasma concentration time of Osimeritinib
  reaches within 6 hours
• Distribution
• Volume of distribution 918L
• Human Plasma protein bound to Osimeritinib is 95

10
ADME PROPERTIES

• Metabolism
• The metabolism of Osimeritinib is occurs via
  oxidation.
• The Two pharmacologically active metabolite of
  Osimeritinib are AZ7550 AZ5104
• Excretion
• The mean terminal half-life period 48 hours
• Clearance value 14.3L/hr
• 68 of metabolite is excreted in feces 14
  through urine
• 2 of unchanged form of drug is eliminated

11
DOSAGE MANAGEMENT
12

• The recommended dosage of Tagrisso 80mg
  tablets are, 80mg tablet should be taken as a
  single dose.
• Tagrisso tablet should be administered with or
  without food.
• If patient felt difficult to swallow the Tagrisso
  tablets as such, must disperse the tablet in 60ml
  of noncarbonated water and drink the solution
  immediately.
• Tagrisso tablet do not break, crush or chew.

13
Interrupt the treatment during the conditions
like

• Interstitial lung disease
• QT prolongation
• Symptomatic congestive heart failure
• In pain management
• Grade III or severe discontinue the Tagrisso
  tablet for 3 weeks

14

• Grade 0 to II follow at 80mg or 40mg as a single
  dose
• If no development in 3 weeks Discontinue the
  therapy.
• While co administration of Tagrisso with CYP3A4
  inducers, the dosage of Tagrisso 80mg should be
  increased to 160mg as a single dose and followed
  by 80mg for 3 weeks after discontinuation of
  strong CYP3A4 inducers.

15
PRECAUTIONS
16

• Interstitial lung disease
• To avoid this problem, withheld or stop
  the Tagrisso 80mg tablets.

17

• Keratitis
• check the manifestation of keratitis regularly
  and provide supportive measures

18

• Embryo fetal toxicityTagrisso 80mg
  tablet required in pr
• QTc extension
• Do not concurrent use of Tagrisso 80mg with drug
  prolong the QTc
• egnancy period causes fetal damage.

19

• Cardiomyopathy
• Periodic cardiac monitoring is assessed in this
  condition stop the therapy.

20
SIDE EFFECTS

• The most common adverse effects occurred during
  the therapy
• Cardiomyopathy, QT prolongation, Interstitial
  lung disease, Keratitis.
• Other common side effect
• Diarrhea or constipation, Hyperglycemia,
  Hypomagnesemia, Hyponatremia, Elevation of AST
  ALT, Stomatitis, Nausea, Vomiting, Rash, Nail
  toxicity, Pruritus, Dry skin, Headache, Cough,
  Dyspnea, Fatigue, Pyrexia, Loss of appetite,
  Respiratory tract infection, Lymphopenia,
  Thrombocytopenia, Anemia, Neutropenia.

21

• PREGNANCY
• Pregnancy category of Osimeritinib is not
  designate
• While using Tagrisso 80mg tablet causes possible
  for fetal harm.
• LACTATION
• Milk feeding should not be taken during lactation
  period.
• STORAGE
• The Tagrisso 80mg tablet is, stored at 25C.
• Keep the tablet carton from moisture, heat and
  light.

22

• MISSED DOSE
• In case of missed dose, do not take the missed
  dose and follow the regular dosing schedule.

23
CONTACT US

• PHONE NO91-9940472902
•  EMAIL       millionhealthpharmaceuticals_at_gmail.c
  om 
•  WEBSITE  https//millionpharma.com/osimeritinib-
  80mg.php

24